Last quarter (Q4 2022), PYC Therapeutics Limited's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, PYC Therapeutics Limited's net income was AU$―. See PYC Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	-	AU$ 30.21M	AU$ 21.83M	AU$ 9.74M	AU$ 7.10M	AU$ 9.77M
Operating Income	-	AU$ -30.21M	AU$ -21.83M	AU$ -9.74M	AU$ -7.10M	AU$ -9.77M
Net Non Operating Interest Income Expense	-	AU$ -8.17K	AU$ 69.68K	AU$ 207.03K	AU$ 117.96K	AU$ 114.88K
Other Income Expense	-	AU$ 15.92M	AU$ 3.13M	AU$ 62.50K	AU$ 250.00	AU$ 48.46K
Pretax Income	-	AU$ -14.29M	AU$ -18.63M	AU$ -9.48M	AU$ -6.98M	AU$ -9.60M
Tax Provision	-	AU$ 0.00	AU$ 0.00	AU$ -2.40M	AU$ -2.90M	AU$ -2.17M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	AU$ -13.86M	AU$ -17.77M	AU$ -6.82M	AU$ -4.08M	AU$ -7.43M
Basic EPS	-	AU$ >-0.01	AU$ >-0.01	AU$ >-0.01	AU$ >-0.01	-
Diluted EPS	-	AU$ >-0.01	AU$ >-0.01	AU$ >-0.01	AU$ >-0.01	-
Basic Average Shares	-	AU$ 3.18B	AU$ 3.09B	AU$ 2.64B	AU$ 2.40B	-
Diluted Average Shares	-	AU$ 3.18B	AU$ 3.09B	AU$ 2.64B	AU$ 2.40B	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	-	AU$ -13.86M	AU$ -17.77M	AU$ -6.82M	AU$ -4.08M	AU$ -7.43M
Normalized Income	-	AU$ -13.86M	AU$ -17.77M	AU$ -6.82M	AU$ -4.08M	AU$ -7.43M
Interest Expense	-	AU$ 32.59K	AU$ 38.82K	-	-	-
EBIT	-	AU$ -14.26M	AU$ -18.59M	AU$ -9.74M	AU$ -7.10M	AU$ -9.77M
EBITDA	-	AU$ -13.42M	AU$ -17.97M	AU$ -9.20M	AU$ -6.97M	AU$ -9.69M

Currency in AUD

PYC Therapeutics Limited Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing